Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among adults aged 18 and over: United States, 2017-2018. NCHS Data Brief. 2020;364:1–8.

Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–115.

CAS  Google Scholar 

Fatani N, Dixon DL, Van Tassell BW, Fanikos J, Buckley LF. Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension. J Am Coll Cardiol. 2021;77:1290–9.

Article  Google Scholar 

Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–210.

Article  Google Scholar 

Mogi M, Maruhashi T, Higashi Y, Masuda T, Nagata D, Nagai M, et al. Update on hypertension research in 2021. Hypertens Res. 2022;45:1276–97.

Article  Google Scholar 

Kodani E, Inoue H, Atarashi H, Okumura K, Suzuki S, Yamashita T, et al. Impact of systolic blood pressure time in target range on adverse events in patients with nonvalvular atrial fibrillation (from the J-RHYTHM Registry). Am J Cardiol. 2022;180:52–8.

Chen K, Li C, Cornelius V, Yu D, Wang Q, Shi R, et al. Prognostic value of time in blood pressure target range among patients with heart failure. JACC Heart Fail. 2022;10:369–79.

Article  Google Scholar 

Bakris G, Sternlicht H. Time in therapeutic range: redefining “optimal” blood pressure control. J Am Coll Cardiol. 2021;77:1300–1.

Article  Google Scholar 

Reiffel JA. Time in the therapeutic range (TTR): an overly simplified conundrum. J Innov Card Rhythm Manag. 2017;8:2643–6.

Article  Google Scholar 

Ng DL, Malik N, Chai CS, Goh GM, Tan SB, Bee PC, et al. Time in therapeutic range, quality of life and treatment satisfaction of patients on long-term warfarin for non-valvular atrial fibrillation: a cross-sectional study. Health Qual Life Outcomes. 2020;18:347.

Article  Google Scholar 

Gateman D, Trojnar ME, Agarwal G. Time in therapeutic range: Warfarin anticoagulation for atrial fibrillation in a community-based practice. Can Fam Physician. 2017;63:e425–31.

Google Scholar 

Huang R, Lin Y, Liu M, Xiong Z, Zhang S, Zhong X, et al. Time in target range for systolic blood pressure and cardiovascular outcomes in patients with heart failure with preserved ejection fraction. J Am Heart Assoc. 2022;11:e022765.

Article  Google Scholar 

Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–31.

Article  CAS  Google Scholar 

Mancia G, Kjeldsen SE, Zappe DH, Holzhauer B, Hua TA, Zanchetti A, et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J. 2016;37:955–64.

Article  CAS  Google Scholar 

Wright JT Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16.

Article  CAS  Google Scholar 

Cruickshank JM. Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction. BMJ. 1988;297:1227–30.

Article  CAS  Google Scholar 

Doumas M, Tsioufis C, Fletcher R, Amdur R, Faselis C, Papademetriou V. Time in therapeutic range, as a determinant of all-cause mortality in patients with hypertension. J Am Heart Assoc. 2017;6:e007131.

Lloyd-Jones DM. Cumulative blood pressure measurement for cardiovascular disease prediction: promise and pitfalls. J Am Coll Cardiol. 2022;80:1156–8.

Article  Google Scholar